Resumen
Hundreds of medications commonly prescribed for anticancer treatments and some infections are known to cause hearing damage, referred to as ototoxicity. Preventing or minimizing ototoxicity is critical in order to preserve quality of life for patients receiving treatment and to reduce the societal burden of hearing loss. Current clinical evaluations are restricted to a limited frequency range (=8 kHz); however, this approach does not permit the earliest detection of ototoxicity, most likely to be observed at the highest frequencies (9?20 kHz). Distortion product otoacoustic emissions (DPOAEs) offer a noninvasive, objective approach to monitor cochlear health in those unable to respond via conventional methods. The current report analyzes different DPOAE paradigms used in patients undergoing chemotherapy treatments with various platinum derivatives. Individualized serial monitoring protocols were completed at the highest frequencies with measurable DPOAEs. This allowed the exploration of potential clinical translation opportunities for further quantification of the earliest signs of underlying cochlear damage, which may go undetected with conventional methods. Clinical practice has the potential to be enhanced by emerging DPOAE applications, including targeted monitoring protocols and high-frequency stimuli to assess cochlear function, especially at the highest frequencies, and advanced calibration techniques to ensure the stability of serial measurements.